Isthmus Partners’s DexCom DXCM Stock Holding History

Isthmus Partners’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$16M	Sell	185,580 -686	-0.4%	-$57.1K	1.54%	17
2026 Q2	$12.5M	Buy	186,266 +3,612	+2%	+$241K	1.21%	30
2026 Q1	$11.5M	Buy	182,654 +6,201	+4%	+$432K	1.2%	41
2025 Q4	$11.7M	Buy	176,453 +8,667	+5%	+$560K	1.3%	31
2025 Q3	$11.3K	Buy	167,786 +399	+0.2%	+$31.6K	﹤0.01%	138
2025 Q2	$14.6M	Buy	+167,387	New	+$13.1M	1.71%	17

Other funds holding DXCM

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Isthmus Partners's DXCM Position: Q3 2026 in Review

Isthmus Partners reduced its DexCom (DXCM) stake by 0.37% in Q3 2026, selling an estimated $57.1K and leaving 185,580 shares worth $16M. The position accounts for 1.54% of the portfolio, ranked #17.

Isthmus Partners first reported a position in DXCM in Q2 2025 and has held it in 6 quarters since. 863 funds tracked by Wall St. Rank hold DXCM as of Q3 2026.

Isthmus Partners held 185,580 shares of DexCom worth $16M as of Q3 2026.
Isthmus Partners sold 686 DexCom shares in Q3 2026, an estimated $57.1K.
DexCom made up 1.54% of Isthmus Partners's portfolio in Q3 2026, its #17 holding.
Isthmus Partners first reported a position in DexCom in Q2 2025 and has held it in 6 quarters since.
863 funds tracked by Wall St. Rank held DexCom as of Q3 2026.

Based on Isthmus Partners's 13F filing for Q3 2026, filed 21 Oct 2026.